BELLUS Health Inc. (TSE:BLU – Get Free Report) shares passed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of C$19.48 and traded as high as C$19.61. BELLUS Health shares last traded at C$19.48, with a volume of 28,666 shares changing hands.
BELLUS Health Stock Performance
The firm has a market cap of C$2.47 billion, a PE ratio of -20.29 and a beta of -0.28. The company has a debt-to-equity ratio of 0.32, a current ratio of 33.42 and a quick ratio of 16.40. The firm has a fifty day moving average of C$19.48.
BELLUS Health Company Profile
BELLUS Health Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus.
Further Reading
- Five stocks we like better than BELLUS Health
- What is the S&P/TSX Index?
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- Why Invest in 5G? How to Invest in 5G Stocks
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- How to Effectively Use the MarketBeat Ratings Screener
- 5 Oversold Stocks to Buy Right Now
Receive News & Ratings for BELLUS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BELLUS Health and related companies with MarketBeat.com's FREE daily email newsletter.